It was an absolute pleasure to speak with Dr Kenneth Cusi (University of Florida, Gainesville, FL, USA) about the novel compound PXL770 and the results of the STAMP-NAFLD phase 2 trial investigating its potential in NASH.
His abstract entitled ‘Human proof-of-concept in non-alcoholic liver disease (NAFLD) patients with PXL770, a novel first-in-class direct AMP-kinase activator — STAMP-NAFLD Phase 2a trial’ was presented at the International Liver Congress (ILC) 2021, 23-26 June.
- PXL770 is a novel drug, could you tell us a little about its mechanism of action and the rationale for its potential use in metabolic disorders, such as NASH? (0:15)
- Could you give us a brief overview of the STAMP-NAFLD Phase 2a trial, including the overall aim, design and outcome measures? (1:38)
- What has the study demonstrated in terms of clinical efficacy and safety? (2:25)
- On the basis of these findings, do you think that PXL770 offers a promising therapeutic approach for NASH, and if so, which patients could see the largest benefit? (4:04)
Disclosures: K.C. has received research support towards the University of Florida as principal investigator from the National Institute of Health (NIH), Cirius, Echosens, Inventiva, Novartis, Novo Nordisk, Poxel, and Zydus. K.C. is also a consultant for Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal, and Novo Nordisk.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Quentin Anstee: Highlights from the Digital NAFLD Summit 2021
touchENDOCRINOLOGY joins Professor Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Are you pleased with how the European Association for the Study of the Liver (EASL) NAFLD Summit 2021 went this year? (00:23-01:00) 2. What were […]
Quentin Anstee, Digital NAFLD Summit 2021: Exciting Advances and New Research into the Management of Non-alcoholic Fatty Liver Disease
touchENDOCRINOLOGY joins Professor Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Please summarise the prevalence of non-alcoholic fatty liver disease (NAFLD) and the clinical unmet needs in this area? (00:20-01:00) 2. What are the current most […]
Jean-François Dufour, UEG 2021: Treatment Pipeline for NASH
It was a pleasure to speak with Prof. Jean-François Dufour (University of Bern, Bern, Switzerland) about drug development in non-alcoholic steatohepatitis (NASH) and in particular the farnesoid X receptor (FXR) as a therapeutic target. His presentation entitled ‘Treatment of NASH: What is in the pipeline?’ was given at UEG week, 2-5 Oct 2021. Questions What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!